Takeda has supported a series A round for Cerevance as the company is spun out of Rockefeller University's Howard Hughes Medical Institute.
US-based neuroscience company Cerevance was spun out of Rockefeller University today, raising $21.5m in series A funding from investors including drug developer Takeda Pharmaceutical.
Lightstone Ventures led the series A round, which brought Cerevance’s total funding to $36m, though details about previous investments have not been revealed.
Takeda will also provide 25-person neuroscience research team to Cerevance through its Cambridge, UK offices, licences to preclinical and clinical stage drug candidates and access to laboratory equipment.
Cerevance has emerged out of…
